All cause 90-day mortality associated with TUR-P procedure: a Swedish quality register-based study (2013–2022)
DOI:
https://doi.org/10.2340/sju.v61.46751Keywords:
Prostate hyperplasia, transurethral resection of prostate (TUR-P), perioperative mortality rate (POMR), age, ASAAbstract
Prostatic hyperplasia is among the most common urological conditions in ageing men, and transurethral resection of the prostate (TUR-P) has long been the standard surgical treatment. The perioperative mortality rate (POMR) is an important quality indicator for surgical care, yet contemporary national Swedish POMR data associated with TUR-P is lacking.
Aims: The primary aim was to assess all-cause mortality up to 90-days following TUR-P in Sweden
2013–2022 and whether there was any temporal trend in POMR. The secondary aim was to assess the impact of patients’ characteristics (age, ASA class and indication).
Material and Methods: This was an observational, register-based cohort study using data from the Swedish-Perioperative-Register (SPOR). A total of 14,052 TUR-P procedures (KED22) for benign prostatic hyperplasia or prostate cancer were included. Descriptive statistics, ANOVA, chi-square test, and multivariable-logistic regression were applied.
Results: A total of 10 patients died within 30-days (0.07%) and 56 within 90-days (0.4%). No difference in annual POMR was seen over the study-period. Increasing age, higher ASA-class and cancer indication were the only independent predictors of 90-day mortality. Patients aged above 80-years had an OR of 7.9 (95% confidence interval [CI]: 2.2–42.3), ASA 4 had an OR of 12.6 (95% CI: 1.7–94.3), and cancer diagnosis had an OR of 4.4 (95% CI: 2.5–7.9) in the multivariable logistic regression.
Conclusions: POMR following TUR-P in Sweden is low and numerically similar to age-adjusted background mortality in the Swedish population up to the age of 70-years. High age, ASA-class and cancer diagnosis are the strongest predictors of postoperative mortality.
Downloads
References
GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2022;3(11):e754–e776.
Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211(1):11–19. DOI: https://doi.org/10.1097/JU.0000000000003698
Cornu JN, Ahyai S, Bachmann A, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67(6):1066–1096. DOI: https://doi.org/10.1016/j.eururo.2014.06.017
Mayer EK, Kroeze SGC, Chopra S, et al. Examining the ‘gold standard’: a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU Int. 2012;110(11):1595–1601. DOI: https://doi.org/10.1111/j.1464-410X.2012.11119.x
Cornu JN, Zantek P, Burtt G, et al. Minimally invasive treatments for benign prostatic obstruction: a systematic review and network meta-analysis. Eur Urol. 2023;83(6):534–547. DOI: https://doi.org/10.1016/j.eururo.2023.02.028
Rassweiler J, Teber D, Kuntz R, et al. Complications of transurethral resection of the prostate (TURP) – incidence, management, and prevention. Eur Urol. 2006;50(5):969–979; discussion 980. DOI: https://doi.org/10.1016/j.eururo.2005.12.042
Watters DA, Hollands MJ, Gruen RL, et al. Perioperative mortality rate (POMR): a global indicator of access to safe surgery and anaesthesia. World J Surg. 2015;39(4):856–864. DOI: https://doi.org/10.1007/s00268-014-2638-4
Davies JI, Gelb AW, Gore-Booth J, et al. Global surgery, obstetric, and anaesthesia indicator definitions and reporting: an Utstein consensus report. PLoS Med. 2021;18(8):e1003749. DOI: https://doi.org/10.1371/journal.pmed.1003749
Eredics K, Wachabauer D, Röthlin F, et al. Reoperation rates and mortality after transurethral and open prostatectomy in a long-term nationwide analysis: have we improved over a decade? Urology. 2018;118:152–157. DOI: https://doi.org/10.1016/j.urology.2018.04.032
Salmivalli A, Ettala O, Boström PJ, et al. Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study. World J Urol. 2022;40(7):1785–1791. DOI: https://doi.org/10.1007/s00345-022-03999-0
Holmström B, Enlund G, Spetz P, et al. The Swedish Perioperative Register: description, validation of data mapping and utility. Acta Anaesthesiol Scand. 2023;67(2):233–239. DOI: https://doi.org/10.1111/aas.14174
Holmström B, Enlund G, Frostell C, et al. SPOR covers 100 percent of publicly run surgical care. Lakartidningen. 2024;121:23197.
Kilhamn N, Eriksson J, von Oelreich E, et al. Age, ASA physical status and surgical outcomes: insights from a nationwide cohort study. Anaesthesia. 2026;81(2):188–200. DOI: https://doi.org/10.1111/anae.16723
Issmail L, Albert J, Frostell C, et al. All-cause 30-day mortality associated with hysterectomy in Sweden from 2015 to 2021 using data from the Swedish perioperative register. Clin Epidemiol Glob Health. 2024;29:101727. DOI: https://doi.org/10.1016/j.cegh.2024.101727
Magnusson J, Karlsson J, Sköldenberg O, et al. Difference in early all-cause mortality among patients having hip arthroplasty a Swedish perioperative registry study 2013–2022. J Orthop Surg Res. 2024;19(1):295. DOI: https://doi.org/10.1186/s13018-024-04752-6
Gavria S, Karlsson J, Albert J, et al. Low all-cause 90-day mortality after revision knee arthroplasty: a study based on the Swedish Perioperative Register (SPOR), 2017–2022. J Exp Orthop. 2026;13(1):e70682. DOI: https://doi.org/10.1002/jeo2.70682
Marchioni M, Primiceri G, Veccia A, et al. Transurethral prostate surgery in prostate cancer patients: a population-based comparative analysis of complication and mortality rates. Asian J Urol. 2024;11(1):48–54. DOI: https://doi.org/10.1016/j.ajur.2022.05.008
Marchioni M, Cindolo L, Di Nicola M, et al. Major acute cardiovascular events after transurethral prostate surgery: a population-based analysis. Urology. 2019;131:196–203. DOI: https://doi.org/10.1016/j.urology.2019.05.014
Patel HD, Ball MW, Cohen JE, et al. Morbidity of urologic surgical procedures: an analysis of rates, risk factors, and outcomes. Urology. 2015;85(3):552–559. DOI: https://doi.org/10.1016/j.urology.2014.11.034
Sankar A, Johnson SR, Beattie WS, et al. Reliability of the American Society of Anesthesiologists physical status scale in clinical practice. Br J Anaesth. 2014;113(3):424–432. DOI: https://doi.org/10.1093/bja/aeu100
Salmivalli A, Boström P, Nurminen P, et al. National trends of surgery for benign prostatic hyperplasia in Finland. Scand J Urol. 2024;59:70–75. DOI: https://doi.org/10.2340/sju.v59.32425
Arch A, Thamsborg A, Winck-Flyvholm L, et al. Thermo-expandable intraprostatic nitinol stents in the treatment of bladder outlet obstruction: a consecutive case series. Scand J Urol. 2024;59:169–172. DOI: https://doi.org/10.2340/sju.v59.41991
Bjarnason J, Ingimarsson JP, Thorisson H, et al. Prostate artery embolization for benign prostatic hyperplasia: a retrospective single-center study of clinical outcome. Scand J Urol. 2025;60:130–134. DOI: https://doi.org/10.2340/sju.v60.44137
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Vachik Petrosyan, Maria Cronhjort, Johanna Albert, Truls Gårdemark, Jan Jakobsson
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
